Terazosin and Parkinson's Disease Extension Study

Launched by CEDARS-SINAI MEDICAL CENTER · Oct 26, 2021

Keywords

ClinConnect Summary

The Terazosin and Parkinson's Disease Extension Study is a clinical trial that aims to explore the long-term effects of a medication called terazosin on people who show early signs of Parkinson's disease or have specific symptoms related to the condition. The goal is to see how terazosin may affect changes in brain imaging and to understand how these changes relate to both movement issues and other symptoms tied to Parkinson's disease. This study is currently looking for participants aged 18 to 75 who have already been part of a related study on Parkinson's disease.

To be eligible for this study, participants must have the ability to provide informed consent and must have been enrolled in a previous study on Parkinson's disease. However, certain health conditions would exclude someone from participating, such as severe heart problems, uncontrolled high blood pressure, or certain types of dementia and depression. If you choose to participate, you can expect to undergo assessments that will help the researchers gather information about your symptoms and overall health throughout the study. This trial is an important step in understanding how terazosin might help people with Parkinson's disease and related symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Enrolled in the study "The Effect of alpha1- adrenergic receptor antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease" (STUDY #000540)
• • Capacity to give informed consent
• Exclusion Criteria:
• • Secondary Parkinsonism, including tardive
• • Concurrent dementia defined by a score lower than 22 on The Montreal Cognitive Assessment (MoCA)
• • Concurrent severe depression defined by a Beck Depression Inventory-Fast Screen (BDI fast screen) score greater than 13
• • Comorbidities related to sympathetic nervous system (SNS) hyperactivity
• • Heart failure (LVEF \<45%)
• • Recent myocardial revascularization (\<12 weeks)
• • Hypertension (systolic blood pressure SBP\>150mmHg (millimeters of mercury) or diastolic blood pressure DBP\>100mmHg)
• • Chronic Atrial fibrillation
• • Concurrent Use of Beta-adrenergic antagonist
• • Diabetes mellitus
• • Chronic Obstructive Pulmonary Disease (COPD)
• • Untreated Sever Sleep Apnea; Apnea-Hypopnea Index (AHI) \> 30/h.
• • Severely reduced kidney function (Glomerular Filtration Rate\<30ml/min)
• • Contraindications to the use of terazosin
• • Recent myocardial infarction (\<48 h)
• • Ongoing angina pectoris
• • Cardiogenic shock or prolonged hypotension
• • Breast-feeding
• • Current use of phosphodiesterase type 5 inhibitors: sildenafil (ViagraTM), tadalafil (CialisTM), or vardenafil (LevitraTM)
• • History of priapism (persistent and painful erection)
• • Neurogenic orthostatic hypotension defined as symptomatic decrease in BP \> 20mmHg systolic or \> 10mmHg diastolic and HR increase \< 20bpm on supine to sitting or standing.
• • Blood pressure less than 110 mm Hg systolic at screening or baseline visit
• • Use of investigational drugs within 30 days before screening
• • For female participant, pregnancy, or plans for child-bearing during study period
• • Allergy/hypersensitivity to iodine or study medication